- NCIt
- C4804
Loading cancer entity…
Loading cancer entity…
Clinical trials
21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk | terminated | Phase 2 | 65 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05755269 | Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women | terminated | — | 19 | Mayo ClinicOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03505372 | Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia | terminated | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2020 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials